Q-omics provides the consensus-scored MPHOSPH8 profile across patient tissues and cancer cell-line models. MPHOSPH8 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MPHOSPH8 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, MPHOSPH8 RNA expression shows 21,380 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where MPHOSPH8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MPHOSPH8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MPHOSPH8 survival associations across molecular data types. MPHOSPH8 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MPHOSPH8 RNA expression–survival associations across cancer types. High MPHOSPH8 expression shows unfavorable associations in CESC, COAD and UVM, but favorable associations in KIRC, UCEC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MPHOSPH8 RNA expression.
This table summarizes MPHOSPH8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MPHOSPH8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MPHOSPH8 shows lower tumor expression in THCA, UCEC, BLCA, LUAD and KICH and higher tumor expression in LIHC. The THCA box plot shows higher MPHOSPH8 RNA expression in normal versus tumor tissue (log2 FC = −0.568, t-test p < 0.001).
This table shows molecular features associated with MPHOSPH8 in patient tissues and cancer cell lines. In patient samples, MPHOSPH8 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MPHOSPH8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Lymphoma.
